Clinical Trial Update: Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating intercalating and maintenance gefitinib with chemotherapy for advanced EGFR-mutant non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: Sichuan University | Conditions: Non-small Cell Lung Cancer Metastatic, EGFR Activating Mutation | Phase 4 | Status: TERMINATED